Published in Int J Cancer on April 01, 2002
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res (2005) 1.96
Specificity of ADAR-mediated RNA editing in newly identified targets. RNA (2008) 1.51
Function-informed transcriptome analysis of Drosophila renal tubule. Genome Biol (2004) 1.43
Transcript- and tissue-specific imprinting of a tumour suppressor gene. Hum Mol Genet (2008) 1.13
Human BLCAP transcript: new editing events in normal and cancerous tissues. Int J Cancer (2010) 1.04
An insight into the transcriptome of the digestive tract of the bloodsucking bug, Rhodnius prolixus. PLoS Negl Trop Dis (2014) 1.03
Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics (2009) 0.98
Targeted therapies in the management of metastatic bladder cancer. Biologics (2007) 0.79
Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol (2003) 0.78
Immunoexpression analysis and prognostic value of BLCAP in breast cancer. PLoS One (2012) 0.78
Bladder cancer-associated protein is suppressed in human cervical tumors. Exp Ther Med (2011) 0.75
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics (2004) 1.57
Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int J Cancer (2007) 1.53
Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics (2005) 1.32
Immediate and delayed effects of E-cadherin inhibition on gene regulation and cell motility in human epidermoid carcinoma cells. Mol Cell Biol (2005) 1.15
Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol Cell Proteomics (2002) 1.15
Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol (2009) 1.07
Proteomics in translational cancer research: toward an integrated approach. Cancer Cell (2003) 1.05
Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics (2005) 1.00
Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics (2004) 1.00
Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol Oncol (2009) 0.99
Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics (2009) 0.98
Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics (2008) 0.95
Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Lab Med (2002) 0.94
Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics (2005) 0.93
Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Mol Cell Proteomics (2012) 0.91
Towards discovery-driven translational research in breast cancer. FEBS J (2005) 0.90
Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett (2006) 0.89
Endoplasmic reticulum resident proteins of normal human dermal fibroblasts are the major targets for oxidative stress induced by hydrogen peroxide. Biochem J (2002) 0.89
A single lysis solution for the analysis of tissue samples by different proteomic technologies. Mol Oncol (2008) 0.88
15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol Cell Proteomics (2008) 0.88
Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol (2007) 0.84
Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol Cell Proteomics (2003) 0.84
A combined proteome and ultrastructural localization analysis of 14-3-3 proteins in transformed human amnion (AMA) cells: definition of a framework to study isoform-specific differences. Mol Cell Proteomics (2008) 0.84
Impact of proteomics on bladder cancer research. Pharmacogenomics (2004) 0.83
Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics (2002) 0.82
Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. Mol Oncol (2010) 0.82
Human proteomic databases: a powerful resource for functional genomics in health and disease. Prog Biophys Mol Biol (2002) 0.81
Protein profiling of the human epidermis from the elderly reveals up-regulation of a signature of interferon-gamma-induced polypeptides that includes manganese-superoxide dismutase and the p85beta subunit of phosphatidylinositol 3-kinase. Mol Cell Proteomics (2003) 0.81
Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol Cell Proteomics (2005) 0.79
Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol (2007) 0.79
Immunoexpression analysis and prognostic value of BLCAP in breast cancer. PLoS One (2012) 0.78
Gel-based proteomics: what does MCP expect? Mol Cell Proteomics (2004) 0.77
Clinical proteomics. Mol Cell Proteomics (2008) 0.77
The Human Proteome Organization: a mission to advance proteome knowledge. Mol Cell Proteomics (2002) 0.76
'Tackling cancer in the EU: the role of innovation'. Mol Oncol (2008) 0.76
Proteomic strategies in bladder cancer: From tissue to fluid and back. Proteomics Clin Appl (2008) 0.76
The European Research Council: the 'Mayor Group' report and the Commission's views on basic research and its impact. FEBS Lett (2004) 0.75
A role for Federation of European Biochemical Societies (FEBS) in the European Research Area (ERA). FEBS Lett (2002) 0.75
[Pathogenesis of breast cancer]. Ugeskr Laeger (2007) 0.75
Molecular Oncology journal has moved to open access. Mol Oncol (2017) 0.75
The European Union Sixth Framework Programme (FP6): where we stand and what are the implications of the consultation process. FEBS Lett (2002) 0.75
Promoting basic research in Europe. FEBS Lett (2004) 0.75
Molecular Oncology. Editorial. Mol Oncol (2013) 0.75
A European Research Council for all sciences: a dream that may come true. FEBS Lett (2003) 0.75
Strong support from the scientific community to the idea of establishing a European Research Council within the Life Sciences. FEBS Lett (2003) 0.75